undamentalytics Newsletter
Sign in

Acumen Pharmaceuticals, Inc. (ABOS) stock

Add to watchlist

Add holding +

NASDAQ: ABOS Nasdaq Biotechnology Next results ~January 26, 2027

Acumen Pharmaceuticals, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders0 buying, 9 selling0 purchases and 48 sales by directors and officers, last 12 monthsInsider trades
  • Funds51 adding, 32 cuttingOf 20 active managers that changed their stake, 9 added; quarter to June 30, 2026Fund buyers and sellers

The Fundamentalytics view

Next results ~January 26, 2027 (estimated)

Current signal Results well ahead of expectations: Reported earnings per share beat the analysts' consensus estimate by 11% in the quarter to 2026-09-30, the 3rd beat in the last four quarters.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

Nothing in Acumen Pharmaceuticals, Inc.'s latest figures clears our strength thresholds.

Things to watch

  • Share dilution. Diluted shares rose 11.0% in a year.
  • Volatile shares. Over the past year the shares showed annualised volatility of 123% and a beta of 2.9 against the S&P 500.

Latest results

Earnings per share
-$0.35 against an average estimate of -$0.39: beat by 11.3%
Share reaction
+14.1% in the first session after the results on October 26, 2026, against +1.3% for the S&P 500
Next report
October 26, 2026; average EPS estimate -$0.37

Acumen Pharmaceuticals' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+14.3%
  • 1 week-89.4%
  • 1 month-88.2%
  • This year-88.6%
  • 1 year-89.1%
  • 5 years-98.3%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

EPS (TTM, diluted)
$-1.55

Growth

Share count change
+11.0%

Earnings

Last results
October 26, 2026
Next results (est.)
January 26, 2027

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Announcement
  2. Results
  3. Announcement
  4. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Acumen Pharmaceuticals, Inc. valuation models and calculator

No model value for Acumen Pharmaceuticals, Inc. at the moment. Current status: limited reported history: available models are shown without a Buy/Hold/Sell rating. Available reported financials are shown below.

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: limited reported history: available models are shown without a Buy/Hold/Sell rating.

Valuation models

We value Acumen Pharmaceuticals, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 11.4%: the 10-year Treasury yield (4.9%) plus a beta of 1.43 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no positive earnings in the latest twelve months
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: the model gives no positive value
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: revenue and margins don't support a positive value
Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. — Does not apply: no positive revenue in the latest twelve months
Combined value Weighted average of the models that apply: the primary model (price-to-earnings vs peers) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. — No model applies: the filings don’t yet support a value.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Acumen Pharmaceuticals, Inc. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$1.50 +25% — 0%
Next −$1.51 −1% — 0%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −5.3% on 90 days ago. In the last 30 days, 1 analyst raised Acumen Pharmaceuticals, Inc.'s forecast and 2 cut it.

Consensus EPS forecast Acumen Pharmaceuticals, Inc., last 90 days
−$2.00 −$1.50 −$1.00 −$0.50 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$1.58 Current fiscal year, 60 days ago: −$1.59 Current fiscal year, 30 days ago: −$1.59 Current fiscal year, 7 days ago: −$1.62 Current fiscal year, Now: −$1.50 −$1.50 Next fiscal year, 90 days ago: −$1.51 Next fiscal year, 60 days ago: −$1.43 Next fiscal year, 30 days ago: −$1.43 Next fiscal year, 7 days ago: −$1.43 Next fiscal year, Now: −$1.51 −$1.51

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$1.58−$1.51
60 days ago −$1.59−$1.43
30 days ago −$1.59−$1.43
7 days ago −$1.62−$1.43
Now −$1.50−$1.51

Earnings against estimates

Quarter toEstimateActualSurprise
Sept 2026 −$0.39 −$0.35 +11.3%
Jun 2026 −$0.41 −$0.45 −11.0%
Mar 2026 −$0.46 −$0.33 +28.3%
Dec 2025 −$0.56 −$0.41 +26.3%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, October 26, 2026

No numeric guidance in Acumen Pharmaceuticals, Inc.'s latest earnings release (filed October 26, 2026). Some companies give their outlook only on the earnings call.

Analyst recommendations

6 analysts, Oct 2026
Buy6100%
Hold00%
Sell00%

Monthly trend

  1. Oct 202666
  2. Sep 202666
  3. Aug 202666
  4. Jul 202666

Counts of recommendations published by analysts covering Acumen Pharmaceuticals, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
6.1%
of tradable shares
Days to cover
5.15
at average volume
Short interest, 1 month
+10%
to October 15, 2026
Held by institutions
67%
of shares
Held by insiders
6.8%
of shares
Employees
60
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 20222023202420252026 to date
Return
ABOS−20%−29%−55%+23%−89%
Industry peers (median)−57%−17%−28%−5%−26%
S&P 500−18%+26%+25%+18%+11%
Months that ended higher
ABOS42%42%25%50%64%
S&P 50042%67%75%75%46%
Largest fall from a high during the year
ABOS−54%−81%−63%−53%−94%
S&P 500−25%−10%−8%−19%−9%

Worst fall since July 1, 2021: 99% from July 2, 2021 to October 30, 2026. Getting back needed a 9557% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$0.21 – $3.37
From 52-week high
−92.9%
vs 50-day average
−89.8%
vs 200-day average
−90.4%
Volatility (1 year)
123%
Beta vs S&P 500
2.91

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
4 up, 8 down
typical move ±8.5%
After a week
5 up, 7 down
typical move ±19.3%
After a month
3 up, 8 down
typical move ±13.4%
Results releasedNext dayS&P 500 next day5 days21 days
October 26, 2026 +14.1% +1.3% −87.9% —
August 12, 2026 +3.2% +0.9% +27.5% +18.2%
May 12, 2026 −3.1% +0.4% −15.6% −7.8%
March 26, 2026 −14.1% −3.5% +2.7% −4.2%
November 12, 2025 −8.1% −1.6% −21.3% +8.6%
August 12, 2025 −10.6% +1.4% −2.8% −2.1%
May 13, 2025 −6.7% +0.8% +1.0% +8.6%
March 27, 2025 +2.6% −2.3% −14.8% −11.2%
November 12, 2024 −21.4% −0.3% −25.8% −35.7%
August 13, 2024 −1.8% +2.0% +10.5% −4.3%
May 14, 2024 +13.1% +1.7% +13.4% −21.4%
March 26, 2024 −3.5% +0.7% −8.0% −24.9%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fundamentals

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Dividends, buybacks and capital spending

Diluted share count
+11.0%
year over year

Who owns it

Funds buying and selling
Reported value
$128M
Institutions reporting
96
Shares held vs prior quarter
▲ 4.0%
Positions opened / closed
30 / 17

Top buyers and sellers, Q2 2026: 51 institutions bought and 32 sold ; the biggest buyer was Blackrock, Inc (+2.3M shares) and the biggest seller FMR LLC (−1.1M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
RA Capital Management, L.P. $56.1M 21.0M 43.9% 0.0%
Sands Capital Alternatives, LLC $9.9M 3.7M 7.8% 0.0%
Blackrock, Inc. $6.6M 2.5M 5.2% ▲ 1296.4%
Alyeska Investment Group, L.P. $6.6M 2.5M 5.1% 0.0%
Franklin Resources Inc $6.2M 2.3M 4.8% 0.0%
ADAR1 Capital Management, LLC $5.6M 2.1M 4.4% ▼ 2.1%
Vanguard Capital Management LLC $4.5M 1.7M 3.5% ▲ 11.0%
Knollwood Investment Advisory, LLC $4.3M 1.6M 3.4% 0.0%
Geode Capital Management, LLC $3M 1.1M 2.4% ▲ 174.3%
Ikarian Capital, LLC $2.8M 1.1M 2.2% 0.0%
Hudson Bay Capital Management LP $2.5M 955K 2.0% ▼ 1.4%
Pathstone Holdings, LLC $2.3M 859K 1.8% 0.0%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Acumen Pharmaceuticals, Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $625,712 48 trades by 9 insiders · 86% under pre-set plans
Net ▼ $625,712 net selling
Insider Date Trade Shares Price Value
Porter Derrell Director June 17, 2026 Sell 13,040 $2.33 $30,383
Porter Derrell Director June 16, 2026 Sell 12,800 $2.33 $29,824
Porter Derrell Director June 15, 2026 Sell 6,460 $2.35 $15,181
Fountain Nathan B Director June 9, 2026 Sell 6,400 $2.23 $14,272
Meisner Derek M Chief Legal Officer & Corp Sec March 6, 2026 Sell pre-set plan 2,090 $3.26 $6,813
Meisner Derek M Chief Legal Officer & Corp Sec February 27, 2026 Sell pre-set plan 9,406 $3.01 $28,312
Meisner Derek M Chief Legal Officer & Corp Sec January 28, 2026 Sell pre-set plan 2,671 $3.00 $8,013
Meisner Derek M Chief Legal Officer & Corp Sec January 26, 2026 Sell pre-set plan 15,085 $3.00 $45,255
Meisner Derek M Chief Legal Officer & Corp Sec January 23, 2026 Sell pre-set plan 5,633 $1.90 $10,703
Barton Russell Chief Operating Officer January 22, 2026 Sell pre-set plan 462 $1.84 $850
Oconnell Daniel Joseph Chief Executive Officer January 22, 2026 Sell pre-set plan 2,689 $1.88 $5,055
Zuga Matt CFO & Chief Business Officer January 22, 2026 Sell pre-set plan 1,687 $1.86 $3,138

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around January 26, 2027 estimated from the company's past filing pattern, not announced

  • October 26, 2026
  • August 12, 2026
  • May 12, 2026
  • March 26, 2026
  • November 12, 2025
  • August 12, 2025

Recent SEC filings

Data status

When each part of this page on Acumen Pharmaceuticals, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Acumen Pharmaceuticals, Inc. in brief

What does Acumen Pharmaceuticals, Inc. do?
Acumen Pharmaceuticals, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Acumen Pharmaceuticals, Inc.'s stock ticker?
Acumen Pharmaceuticals, Inc. trades under the ticker ABOS on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
Who are Acumen Pharmaceuticals, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are RA Capital Management, L.P., Sands Capital Alternatives, LLC and Blackrock, Inc. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Are insiders buying or selling Acumen Pharmaceuticals, Inc. stock?
Over the last 12 months, Acumen Pharmaceuticals, Inc.'s directors and officers reported 0 open-market purchases and 48 sales on Form 4. The insider trading page charts every trade.
When is Acumen Pharmaceuticals, Inc.'s next earnings date?
Around January 26, 2027, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Acumen Pharmaceuticals, Inc. announces its own schedule.